Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O15382
UPID:
BCAT2_HUMAN
Alternative names:
Placental protein 18
Alternative UPACC:
O15382; B2RB87; O00269; Q96KG1; Q9BTB6; Q9BUU6
Background:
Branched-chain-amino-acid aminotransferase, mitochondrial, also known as Placental protein 18, plays a pivotal role in the metabolism of essential branched chain amino acids leucine, isoleucine, and valine. Its ability to catalyze the first reaction in their catabolism and potentially function as a transporter highlights its multifaceted role in biological systems.
Therapeutic significance:
The protein's link to Hypervalinemia and hyperleucine-isoleucinemia, a metabolic disorder characterized by elevated plasma concentrations of valine and leucine/isoleucine, underscores its therapeutic significance. The discovery of variants reducing the enzyme's activity and the positive response to vitamin B6 treatment illuminate pathways for targeted therapies, enhancing our understanding of metabolic disorders.